minoxidil ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
vasodilators 1814 38304-91-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • minoxidil
  • loniten
  • rogaine
A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
  • Molecular weight: 209.25
  • Formula: C9H15N5O
  • CLOGP: 0.38
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 93.63
  • ALOGS: -1.02
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.83 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MARK4,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 57
kinase-selectivity-class ACVR2A,ACVR2B,CAMK2D,DDR1,DYRK1B,GRK2,MAP3K21,MAPK7,MARK4,PRKDC,SIK2,STK33,SYK,TEK,TTK,ULK1 16
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.521 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.091 % High 1

Approvals:

DateAgencyCompanyOrphan
Oct. 18, 1979 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertrichosis 185.73 11.42 56 46388 1423 90580580
Synovitis 154.19 11.42 3 46441 329749 90252254
Product dose omission issue 138.96 11.42 395 46049 291292 90290711
Hand deformity 130.04 11.42 5 46439 296357 90285646
Glossodynia 124.37 11.42 11 46433 321768 90260235
Pericarditis 124.15 11.42 3 46441 270148 90311855
Systemic lupus erythematosus 114.74 11.42 23 46421 361873 90220130
Helicobacter infection 102.42 11.42 3 46441 226847 90355156
Product formulation issue 99.45 11.42 29 46415 654 90581349
Fatigue 91.16 11.42 946 45498 1153077 89428926
COVID-19 90.61 11.42 239 46205 168604 90413399
Maternal exposure during pregnancy 89.93 11.42 36 46408 360027 90221976
Contraindicated product administered 88.54 11.42 27 46417 320112 90261891
General physical health deterioration 87.88 11.42 36 46408 355079 90226924
Folliculitis 84.62 11.42 5 46439 204348 90377655
Dermatitis atopic 83.66 11.42 80 46364 23392 90558611
Wound 82.98 11.42 26 46418 302954 90279049
Pleural thickening 82.55 11.42 38 46406 3210 90578793
Presbyacusis 81.75 11.42 37 46407 3005 90578998
Blood magnesium increased 80.80 11.42 38 46406 3370 90578633
Pleural fibrosis 78.86 11.42 38 46406 3558 90578445
Dry eye 73.23 11.42 117 46327 57814 90524189
Infusion related reaction 71.50 11.42 65 46379 416715 90165288
Liver injury 71.15 11.42 4 46440 170563 90411440
Type 2 diabetes mellitus 70.82 11.42 10 46434 203234 90378769
Toxicity to various agents 69.88 11.42 30 46414 287816 90294187
Dry skin 65.99 11.42 142 46302 87931 90494072
Hepatic enzyme increased 65.84 11.42 53 46391 360683 90221320
Deafness neurosensory 65.82 11.42 42 46402 6799 90575204
C-reactive protein increased 63.02 11.42 9 46435 181380 90400623
Epigastric discomfort 61.95 11.42 42 46402 7526 90574477
Lower respiratory tract infection 59.45 11.42 27 46417 250632 90331371
Back pain 58.90 11.42 319 46125 316856 90265147
Injection site pain 58.56 11.42 209 46235 173490 90408513
Alopecia 55.24 11.42 438 46006 494633 90087370
Cyst 54.43 11.42 54 46390 16507 90565496
Headache 53.75 11.42 676 45768 862070 89719933
Impaired healing 52.83 11.42 27 46417 234172 90347831
White blood cell count decreased 50.41 11.42 194 46250 166915 90415088
Pruritus 49.33 11.42 458 45986 541067 90040936
Injection site erythema 48.36 11.42 135 46309 98367 90483636
Confusional state 47.44 11.42 78 46366 386127 90195876
Irritable bowel syndrome 46.66 11.42 24 46420 207424 90374579
Osteopenia 46.23 11.42 58 46386 22944 90559059
Intentional dose omission 45.96 11.42 51 46393 17732 90564271
Drug intolerance 45.71 11.42 101 46343 447490 90134513
Onychoclasis 44.38 11.42 34 46410 7365 90574638
Completed suicide 44.32 11.42 10 46434 145048 90436955
Drug interaction 44.03 11.42 46 46398 276407 90305596
Product administration interrupted 43.42 11.42 42 46402 12450 90569553
Hair texture abnormal 43.18 11.42 28 46416 4659 90577344
Hair growth abnormal 41.53 11.42 25 46419 3651 90578352
Swelling 40.81 11.42 97 46347 418961 90163042
Urinary tract infection 40.04 11.42 281 46163 305351 90276652
Blood potassium increased 39.61 11.42 51 46393 20698 90561305
Stress 39.40 11.42 111 46333 81284 90500719
Ill-defined disorder 39.24 11.42 23 46421 184868 90397135
Feeling abnormal 38.63 11.42 179 46265 167056 90414947
Arthropathy 37.91 11.42 82 46362 366160 90215843
Exposure during pregnancy 37.59 11.42 40 46404 238370 90343633
Therapeutic response unexpected 37.48 11.42 51 46393 21829 90560174
Illness 36.99 11.42 109 46335 81860 90500143
Joint range of motion decreased 36.47 11.42 12 46432 135631 90446372
Skin exfoliation 35.24 11.42 95 46349 67818 90514185
Injury 34.73 11.42 30 46414 197319 90384684
Inappropriate schedule of product administration 34.27 11.42 160 46284 149773 90432230
Wheezing 34.23 11.42 43 46401 238037 90343966
Application site pruritus 33.41 11.42 23 46421 4224 90577779
Fibromyalgia 33.20 11.42 34 46410 206235 90375768
Blister 32.71 11.42 50 46394 254948 90327055
Drug-induced liver injury 32.51 11.42 4 46440 90314 90491689
Full blood count decreased 32.21 11.42 56 46388 29633 90552370
Discomfort 32.20 11.42 57 46387 274278 90307725
Pre-existing condition improved 32.19 11.42 31 46413 9138 90572865
Multiple sclerosis relapse 32.15 11.42 78 46366 52227 90529776
Application site exfoliation 32.06 11.42 11 46433 426 90581577
Constipation 31.71 11.42 249 46195 280146 90301857
Diarrhoea 31.66 11.42 665 45779 938525 89643478
Vision blurred 30.78 11.42 125 46319 110168 90471835
Hot flush 30.65 11.42 83 46361 59405 90522598
Lung disorder 29.93 11.42 20 46424 149863 90432140
Intentional overdose 29.62 11.42 6 46438 93828 90488175
Bone cyst 29.02 11.42 17 46427 2361 90579642
Joint swelling 28.98 11.42 146 46298 503154 90078849
Drug abuse 28.79 11.42 4 46440 82343 90499660
Autoimmune disorder 28.62 11.42 3 46441 76741 90505262
Bursitis 28.47 11.42 16 46428 131638 90450365
Flatulence 27.93 11.42 64 46380 41303 90540700
Somnolence 27.80 11.42 193 46251 208891 90373112
Eczema 27.47 11.42 74 46370 52796 90529207
Peripheral venous disease 27.26 11.42 5 46439 83916 90498087
Grip strength decreased 27.06 11.42 7 46437 92569 90489434
Flushing 26.88 11.42 103 46341 88388 90493615
Red blood cell sedimentation rate increased 26.66 11.42 5 46439 82590 90499413
Surgery 26.59 11.42 66 46378 44821 90537182
Osteosclerosis 26.24 11.42 20 46424 4300 90577703
Acne 26.14 11.42 50 46394 28457 90553546
Prescribed overdose 25.61 11.42 9 46435 97616 90484387
Lip dry 25.32 11.42 10 46434 100945 90481058
Dermatitis contact 25.30 11.42 33 46411 13562 90568441
Pyrexia 25.17 11.42 217 46227 660268 89921735
Burning sensation 24.56 11.42 80 46364 63372 90518631
Psoriatic arthropathy 24.55 11.42 50 46394 228285 90353718
Wound infection 24.38 11.42 12 46432 106390 90475613
Eosinophilic pleural effusion 24.21 11.42 7 46437 153 90581850
Injection site swelling 23.67 11.42 76 46368 59763 90522240
Acute kidney injury 23.30 11.42 85 46359 320302 90261701
Skin lesion 23.26 11.42 56 46388 37309 90544694
Balance disorder 23.21 11.42 105 46339 96975 90485028
Fall 23.18 11.42 361 46083 481449 90100554
Hair colour changes 23.06 11.42 17 46427 3477 90578526
Epilepsy 22.58 11.42 7 46437 82199 90499804
Product preparation error 22.44 11.42 27 46417 10234 90571769
Febrile neutropenia 22.34 11.42 29 46415 158320 90423683
Skin fissures 22.24 11.42 39 46405 20770 90561233
Hypercholesterolaemia 22.19 11.42 12 46432 100880 90481123
Dizziness 22.03 11.42 424 46020 588860 89993143
Injection site alopecia 21.70 11.42 5 46439 42 90581961
Hyperphagia 21.55 11.42 15 46429 2803 90579200
Limb discomfort 21.54 11.42 55 46389 38005 90543998
Abdominal discomfort 21.35 11.42 150 46294 477178 90104825
Therapeutic product effect decreased 21.28 11.42 72 46372 277499 90304504
Injection site bruising 21.20 11.42 67 46377 52240 90529763
Influenza 21.20 11.42 133 46311 139131 90442872
Multiple sclerosis 20.97 11.42 45 46399 27795 90554208
Spinal osteoarthritis 20.61 11.42 36 46408 19112 90562891
Pulmonary fibrosis 20.60 11.42 15 46429 107488 90474515
Injection site mass 20.57 11.42 39 46405 22051 90559952
Treatment failure 20.57 11.42 83 46361 303845 90278158
Dermatitis 20.41 11.42 39 46405 22181 90559822
Vitamin D deficiency 20.21 11.42 34 46410 17522 90564481
Injection site pruritus 20.05 11.42 67 46377 53767 90528236
Hepatic cirrhosis 20.05 11.42 4 46440 63249 90518754
Hypokalaemia 19.56 11.42 23 46421 131093 90450910
Nasal disorder 19.47 11.42 15 46429 3277 90578726
Cough 19.10 11.42 280 46164 368682 90213321
Blood cholesterol abnormal 18.93 11.42 14 46430 2876 90579127
Pain in extremity 18.86 11.42 330 46114 450199 90131804
Nausea 18.72 11.42 720 45724 1109596 89472407
Gait inability 18.50 11.42 29 46415 146427 90435576
Dysgeusia 18.34 11.42 64 46380 52496 90529507
Thrombocytopenia 18.22 11.42 51 46393 208674 90373329
Delirium 18.19 11.42 16 46428 104343 90477660
Oropharyngeal pain 18.15 11.42 111 46333 115076 90466927
Myelosuppression 17.83 11.42 3 46441 53588 90528415
Increased tendency to bruise 17.82 11.42 26 46418 11864 90570139
Skin disorder 17.70 11.42 50 46394 36656 90545347
Sinus disorder 17.68 11.42 48 46396 34399 90547604
Skin burning sensation 17.50 11.42 34 46410 19577 90562426
Therapy interrupted 17.47 11.42 61 46383 50047 90531956
Obesity 17.41 11.42 17 46427 105490 90476513
Product use in unapproved indication 17.34 11.42 255 46189 335981 90246022
Vanishing bile duct syndrome 17.25 11.42 10 46434 1362 90580641
Muscle strain 17.23 11.42 23 46421 9664 90572339
Skin swelling 17.14 11.42 19 46425 6595 90575408
Musculoskeletal discomfort 17.06 11.42 35 46409 20956 90561047
Injection site urticaria 17.02 11.42 32 46412 17979 90564024
Depressed level of consciousness 16.99 11.42 8 46436 72776 90509227
Weight decreased 16.88 11.42 281 46163 379629 90202374
Application site pain 16.65 11.42 16 46428 4704 90577299
Blepharospasm 16.58 11.42 4 46440 55441 90526562
Trichorrhexis 16.51 11.42 10 46434 1477 90580526
Blood pressure increased 16.50 11.42 164 46280 197053 90384950
Anxiety 16.39 11.42 236 46208 309536 90272467
Skin discolouration 16.37 11.42 55 46389 44260 90537743
Muscle spasms 16.27 11.42 199 46245 251684 90330319
Eye swelling 16.15 11.42 42 46402 29344 90552659
Vomiting 16.05 11.42 296 46148 787997 89794006
Mobility decreased 16.01 11.42 70 46374 250664 90331339
Pancytopenia 15.98 11.42 23 46421 120240 90461763
Injection site rash 15.88 11.42 37 46407 24136 90557867
Pregnancy 15.80 11.42 6 46438 62041 90519962
Depressed mood 15.70 11.42 59 46385 50163 90531840
Decreased interest 15.66 11.42 15 46429 4392 90577611
Wrong technique in product usage process 15.34 11.42 75 46369 71496 90510507
Dandruff 15.32 11.42 6 46438 339 90581664
Spinal stenosis 15.29 11.42 30 46414 17394 90564609
Eye irritation 15.15 11.42 45 46399 33933 90548070
Application site dryness 15.14 11.42 5 46439 172 90581831
Spinal operation 14.86 11.42 22 46422 10174 90571829
Nasal congestion 14.84 11.42 83 46361 83331 90498672
Infusion site haemorrhage 14.82 11.42 16 46428 5395 90576608
Expired product administered 14.79 11.42 18 46426 6904 90575099
Hepatitis 14.72 11.42 9 46435 70730 90511273
Rotator cuff syndrome 14.69 11.42 28 46416 15891 90566112
Hyponatraemia 14.55 11.42 29 46415 133509 90448494
Lichen planopilaris 14.54 11.42 5 46439 195 90581808
Ageusia 14.50 11.42 28 46416 16048 90565955
Liver disorder 14.40 11.42 25 46419 121244 90460759
Arthralgia 14.32 11.42 510 45934 778012 89803991
Urinary incontinence 14.21 11.42 47 46397 37519 90544484
Oroticaciduria 14.20 11.42 3 46441 16 90581987
Hip arthroplasty 14.13 11.42 11 46433 76197 90505806
Blood potassium decreased 14.04 11.42 55 46389 47672 90534331
Electrocardiogram QT prolonged 14.02 11.42 10 46434 72446 90509557
Hip fracture 13.99 11.42 43 46401 33034 90548969
Inflammation 13.90 11.42 46 46398 178546 90403457
Infusion site erythema 13.81 11.42 25 46419 13645 90568358
Rosacea 13.80 11.42 16 46428 5831 90576172
Coeliac disease 13.77 11.42 3 46441 44607 90537396
Trigger finger 13.66 11.42 15 46429 5155 90576848
Oral herpes 13.64 11.42 43 46401 33481 90548522
Neutropenia 13.64 11.42 64 46380 224840 90357163
Palpitations 13.60 11.42 118 46326 136610 90445393
Neuropathy peripheral 13.51 11.42 118 46326 136852 90445151
Bone hypertrophy 13.45 11.42 6 46438 471 90581532
Ocular hyperaemia 13.43 11.42 43 46401 33755 90548248
Neuralgia 13.37 11.42 41 46403 31459 90550544
Sleep disorder therapy 13.34 11.42 6 46438 480 90581523
Therapy cessation 13.32 11.42 45 46399 36316 90545687
Foreign body in reproductive tract 13.28 11.42 8 46436 1169 90580834
Cardiac hypertrophy 13.28 11.42 8 46436 1170 90580833
Blood uric acid increased 13.26 11.42 18 46426 7686 90574317
Glomerulonephritis acute 13.21 11.42 4 46440 103 90581900
Upper-airway cough syndrome 13.21 11.42 26 46418 15109 90566894
Product container issue 13.03 11.42 10 46434 2171 90579832
Application site warmth 13.02 11.42 5 46439 268 90581735
Psoriasis 12.91 11.42 124 46320 147630 90434373
Blood uric acid decreased 12.85 11.42 7 46437 846 90581157
Rhinorrhoea 12.61 11.42 83 46361 88233 90493770
Onychomadesis 12.48 11.42 4 46440 45994 90536009
Erythema annulare 12.30 11.42 5 46439 312 90581691
Gastrointestinal candidiasis 12.30 11.42 5 46439 312 90581691
Full blood count abnormal 12.28 11.42 44 46400 36553 90545450
Product use issue 12.26 11.42 109 46335 329810 90252193
Epistaxis 12.15 11.42 80 46364 85045 90496958
Polyarteritis nodosa 12.13 11.42 5 46439 323 90581680
Anal pruritus 12.03 11.42 7 46437 960 90581043
Pinguecula 12.02 11.42 4 46440 141 90581862
Deformity 11.97 11.42 22 46422 12148 90569855
Retinal disorder 11.91 11.42 9 46435 1910 90580093
Interstitial lung disease 11.83 11.42 13 46431 76392 90505611
Seasonal allergy 11.77 11.42 32 46412 22951 90559052
Cardiac disorder 11.77 11.42 59 46385 56813 90525190
Application site irritation 11.74 11.42 9 46435 1952 90580051
Metabolic acidosis 11.70 11.42 7 46437 55669 90526334
Influenza like illness 11.65 11.42 76 46368 80535 90501468
Knee operation 11.63 11.42 16 46428 6920 90575083
Hypoacusis 11.59 11.42 36 46408 27814 90554189
Acrochordon 11.56 11.42 8 46436 1481 90580522
Alopecia areata 11.52 11.42 9 46435 2006 90579997
Analgesic therapy 11.49 11.42 6 46438 666 90581337
Medication error 11.43 11.42 16 46428 84636 90497367
Application site vesicles 11.43 11.42 8 46436 1509 90580494

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertrichosis 272.75 18.01 60 16729 538 42604008
Product formulation issue 218.96 18.01 53 16736 748 42603798
Fractional exhaled nitric oxide increased 204.69 18.01 58 16731 1551 42602995
Myoglobin blood increased 161.19 18.01 59 16730 3623 42600923
Plantar fasciitis 156.25 18.01 55 16734 3015 42601531
Sensation of foreign body 154.85 18.01 57 16732 3556 42600990
Pericardial effusion 138.72 18.01 105 16684 29170 42575376
Brain natriuretic peptide increased 129.57 18.01 60 16729 6710 42597836
Hyperphosphataemia 120.92 18.01 71 16718 12933 42591613
Myasthenia gravis 109.24 18.01 72 16717 16065 42588481
Appendicolith 108.39 18.01 67 16722 13389 42591157
Analgesic therapy 101.05 18.01 50 16739 6474 42598072
Exostosis 98.79 18.01 47 16742 5584 42598962
Incorrect route of product administration 93.24 18.01 77 16712 24228 42580318
Drug therapy 93.22 18.01 47 16742 6333 42598213
Sleep disorder therapy 92.64 18.01 48 16741 6846 42597700
Blood phosphorus increased 92.43 18.01 59 16730 12466 42592080
Appendicitis 91.19 18.01 71 16718 20542 42584004
Activated partial thromboplastin time prolonged 91.10 18.01 64 16725 15839 42588707
Stress 83.76 18.01 95 16694 44117 42560429
Secretion discharge 82.53 18.01 46 16743 7589 42596957
Hypophosphataemia 79.59 18.01 66 16723 20879 42583667
Coronary artery disease 75.10 18.01 99 16690 53621 42550925
Anticoagulant therapy 73.94 18.01 36 16753 4499 42600047
Antacid therapy 72.60 18.01 36 16753 4681 42599865
Obstructive airways disorder 71.97 18.01 67 16722 24692 42579854
Swelling 71.91 18.01 98 16691 54787 42549759
Neuralgia 71.86 18.01 68 16721 25579 42578967
Ventricular fibrillation 66.21 18.01 70 16719 30053 42574493
Micturition urgency 66.09 18.01 47 16742 11851 42592695
Dysphonia 64.11 18.01 67 16722 28383 42576163
Bacterial infection 63.44 18.01 66 16723 27813 42576733
Blood uric acid increased 63.28 18.01 51 16738 15496 42589050
Sleep disorder 63.18 18.01 86 16703 48009 42556537
Blood calcium increased 62.81 18.01 40 16749 8414 42596132
End stage renal disease 62.54 18.01 52 16737 16506 42588040
Dyspnoea exertional 60.39 18.01 86 16703 50062 42554484
Iron deficiency 59.85 18.01 43 16746 11018 42593528
Congenital hiatus hernia 58.14 18.01 34 16755 6140 42598406
Ascites 57.93 18.01 90 16699 56588 42547958
Cardiac disorder 56.12 18.01 82 16707 48850 42555696
Abdominal distension 54.79 18.01 100 16689 71635 42532911
Blood test abnormal 53.94 18.01 43 16746 12863 42591683
Cardiogenic shock 53.41 18.01 68 16721 35572 42568974
Bronchopulmonary aspergillosis allergic 53.26 18.01 29 16760 4569 42599977
Blood cholesterol increased 51.54 18.01 58 16731 26683 42577863
Eosinophilia 51.25 18.01 64 16725 32835 42571711
Dry mouth 48.91 18.01 69 16720 39810 42564736
Ulcer 48.75 18.01 45 16744 16396 42588150
Needle fatigue 47.81 18.01 18 16771 1195 42603351
Hyperlipidaemia 47.27 18.01 50 16739 21466 42583080
Gait spastic 45.19 18.01 18 16771 1391 42603155
Troponin increased 44.93 18.01 46 16743 19016 42585530
Thrombosis 44.30 18.01 89 16700 68422 42536124
Relapsing-remitting multiple sclerosis 44.16 18.01 18 16771 1477 42603069
Increased upper airway secretion 43.81 18.01 21 16768 2535 42602011
Intentional product misuse 43.16 18.01 83 16706 61817 42542729
Erectile dysfunction 42.92 18.01 51 16738 24862 42579684
Total lung capacity decreased 42.70 18.01 23 16766 3547 42600999
Pneumothorax 41.89 18.01 49 16740 23494 42581052
Chest discomfort 41.56 18.01 83 16706 63533 42541013
Gout 41.20 18.01 53 16736 28002 42576544
Hypertonic bladder 39.11 18.01 19 16770 2362 42602184
Drug interaction 38.99 18.01 29 16760 266970 42337576
Product label on wrong product 38.76 18.01 8 16781 51 42604495
Diabetes mellitus 37.59 18.01 77 16712 60010 42544536
Drug hypersensitivity 36.88 18.01 104 16685 99285 42505261
Cardiac tamponade 36.70 18.01 26 16763 6514 42598032
Aspiration 36.54 18.01 40 16749 17846 42586700
Wheezing 36.41 18.01 72 16717 54709 42549837
Foreign body in throat 36.27 18.01 12 16777 544 42604002
Febrile neutropenia 34.48 18.01 15 16774 185688 42418858
Renal cyst haemorrhage 33.73 18.01 12 16777 678 42603868
Oedema peripheral 32.91 18.01 123 16666 135953 42468593
Thrombocytopenia 32.83 18.01 17 16772 190262 42414284
Chronic obstructive pulmonary disease 32.75 18.01 75 16714 63039 42541507
Pleuritic pain 32.64 18.01 25 16764 7052 42597494
Monoparesis 32.44 18.01 18 16771 2942 42601604
Rectal prolapse 32.07 18.01 11 16778 557 42603989
Aortic stenosis 32.05 18.01 27 16762 8718 42595828
Mixed anxiety and depressive disorder 31.99 18.01 9 16780 234 42604312
Bacteroides infection 31.87 18.01 17 16772 2570 42601976
Ceruloplasmin increased 31.81 18.01 6 16783 22 42604524
Benign prostatic hyperplasia 31.26 18.01 40 16749 21012 42583534
Blood copper increased 30.64 18.01 6 16783 28 42604518
Lung opacity 30.00 18.01 22 16767 5815 42598731
Neutropenia 29.95 18.01 21 16768 199410 42405136
Nephrogenic systemic fibrosis 29.63 18.01 18 16771 3483 42601063
Loss of libido 29.15 18.01 17 16772 3053 42601493
Toxicity to various agents 27.32 18.01 30 16759 229106 42375440
Septic shock 25.68 18.01 3 16786 91669 42512877
Vascular anastomotic haemorrhage 25.51 18.01 8 16781 305 42604241
Multiple organ dysfunction syndrome 25.38 18.01 90 16699 96945 42507601
Muscle spasms 25.30 18.01 83 16706 85961 42518585
Muscle spasticity 24.87 18.01 21 16768 6801 42597745
General physical health deterioration 24.42 18.01 121 16668 151125 42453421
Vascular compression 23.70 18.01 8 16781 386 42604160
Joint injury 23.57 18.01 29 16760 14647 42589899
Hyponatraemia 23.10 18.01 90 16699 101372 42503174
Cardiovascular disorder 22.42 18.01 27 16762 13338 42591208
Nasopharyngitis 22.04 18.01 78 16711 83918 42520628
Pollakiuria 21.95 18.01 35 16754 22470 42582076
Abdominal wall haemorrhage 21.56 18.01 8 16781 510 42604036
Breath sounds abnormal 21.22 18.01 25 16764 12068 42592478
Electrocardiogram ST-T segment depression 21.13 18.01 4 16785 15 42604531
Interstitial lung disease 20.93 18.01 3 16786 78459 42526087
Blood 25-hydroxycholecalciferol decreased 20.77 18.01 7 16782 336 42604210
Pleuropericarditis 20.77 18.01 7 16782 336 42604210
Vena cava injury 20.75 18.01 7 16782 337 42604209
Aortic dilatation 20.65 18.01 11 16778 1658 42602888
Disease progression 20.43 18.01 16 16773 143640 42460906
Hypertension 20.42 18.01 124 16665 167080 42437466
Central nervous system lesion 20.40 18.01 20 16769 7850 42596696
Hypercholesterolaemia 20.00 18.01 25 16764 12824 42591722
Malignant neoplasm progression 19.72 18.01 9 16780 108391 42496155
Hyperparathyroidism secondary 19.63 18.01 11 16778 1831 42602715
Pancytopenia 19.59 18.01 11 16778 117732 42486814
Respiratory symptom 19.56 18.01 23 16766 11083 42593463
Scrotal oedema 19.32 18.01 11 16778 1888 42602658
Left ventricular hypertrophy 19.31 18.01 21 16768 9298 42595248
Acute kidney injury 19.26 18.01 77 16712 367260 42237286
Pleural effusion 18.81 18.01 82 16707 97084 42507462
Dermatitis contact 18.80 18.01 15 16774 4488 42600058
Hypokalaemia 18.54 18.01 3 16786 71718 42532828
Delayed graft function 18.41 18.01 12 16777 2623 42601923
Intraductal papillary mucinous neoplasm 18.32 18.01 7 16782 484 42604062
Swelling of eyelid 18.16 18.01 11 16778 2117 42602429

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertrichosis 442.41 11.87 112 49636 1666 110537885
Product formulation issue 287.77 11.87 75 49673 1259 110538292
Hyperphosphataemia 118.20 11.87 80 49668 16301 110523250
Appendicolith 113.45 11.87 74 49674 14181 110525370
Analgesic therapy 109.11 11.87 57 49691 7227 110532324
Stress 107.79 11.87 180 49568 105168 110434383
Pericardial effusion 104.77 11.87 129 49619 57088 110482463
Sleep disorder therapy 102.12 11.87 55 49693 7416 110532135
Myasthenia gravis 100.83 11.87 81 49667 21430 110518121
Drug therapy 100.57 11.87 54 49694 7237 110532314
Product dose omission issue 98.93 11.87 344 49404 321438 110218113
Blood phosphorus increased 90.67 11.87 68 49680 16272 110523279
Drug interaction 85.97 11.87 60 49688 500123 110039428
Toxicity to various agents 84.79 11.87 56 49692 480499 110059052
Fractional exhaled nitric oxide increased 82.14 11.87 25 49723 751 110538800
Hand deformity 81.58 11.87 4 49744 218502 110321049
Appendicitis 81.27 11.87 81 49667 28383 110511168
Anticoagulant therapy 80.44 11.87 42 49706 5319 110534232
Blood uric acid increased 80.16 11.87 71 49677 21458 110518093
Antacid therapy 79.54 11.87 42 49706 5442 110534109
Activated partial thromboplastin time prolonged 77.83 11.87 71 49677 22297 110517254
Presbyacusis 75.83 11.87 33 49715 2786 110536765
Alopecia 75.06 11.87 344 49404 364409 110175142
Fatigue 74.86 11.87 855 48893 1215103 109324448
Neuralgia 74.16 11.87 100 49648 48378 110491173
Dermatitis atopic 71.66 11.87 72 49676 25469 110514082
Pleural thickening 69.91 11.87 33 49715 3366 110536185
Helicobacter infection 68.96 11.87 3 49745 181874 110357677
Blood magnesium increased 66.22 11.87 33 49715 3790 110535761
Drug abuse 63.89 11.87 4 49744 177407 110362144
Pleural fibrosis 62.50 11.87 33 49715 4275 110535276
Glossodynia 60.44 11.87 13 49735 221991 110317560
Incorrect route of product administration 59.64 11.87 105 49643 63956 110475595
Hypophosphataemia 59.43 11.87 74 49674 33108 110506443
Wound 59.37 11.87 16 49732 234421 110305130
Pericarditis 59.31 11.87 13 49735 219101 110320450
Micturition urgency 58.92 11.87 57 49691 19263 110520288
Systemic lupus erythematosus 57.90 11.87 21 49727 254317 110285234
Iron deficiency 57.27 11.87 55 49693 18421 110521130
Headache 57.12 11.87 627 49121 881750 109657801
Ventricular fibrillation 56.87 11.87 81 49667 41232 110498319
Congenital hiatus hernia 56.03 11.87 35 49713 6224 110533327
Bacterial infection 55.78 11.87 85 49663 45951 110493600
Liver injury 55.36 11.87 3 49745 150410 110389141
Relapsing-remitting multiple sclerosis 54.79 11.87 24 49724 2058 110537493
End stage renal disease 53.86 11.87 57 49691 21416 110518135
Confusional state 53.48 11.87 80 49668 468600 110070951
C-reactive protein increased 53.10 11.87 16 49732 217903 110321648
Gout 52.27 11.87 73 49675 36493 110503058
Febrile neutropenia 51.78 11.87 40 49708 316727 110222824
Acute kidney injury 51.32 11.87 133 49615 635297 109904254
Type 2 diabetes mellitus 51.15 11.87 9 49739 177223 110362328
Epigastric discomfort 51.09 11.87 38 49710 8977 110530574
Dry skin 50.88 11.87 134 49614 107519 110432032
Blood calcium increased 50.88 11.87 51 49697 17989 110521562
Folliculitis 49.52 11.87 8 49740 167645 110371906
Maternal exposure during pregnancy 48.69 11.87 27 49721 254856 110284695
Infusion related reaction 46.52 11.87 62 49686 381100 110158451
Dry eye 46.29 11.87 87 49661 55706 110483845
Cyst 45.36 11.87 46 49702 16450 110523101
Abdominal distension 45.17 11.87 177 49571 174926 110364625
Needle fatigue 44.76 11.87 18 49730 1246 110538305
Deafness neurosensory 44.61 11.87 36 49712 9583 110529968
Myoglobin blood increased 43.88 11.87 26 49722 4206 110535345
Blood test abnormal 43.82 11.87 59 49689 28495 110511056
COVID-19 43.77 11.87 222 49526 244838 110294713
Thrombosis 43.20 11.87 127 49621 108535 110431016
Hyperlipidaemia 43.16 11.87 66 49682 35782 110503769
Blood potassium increased 42.57 11.87 63 49685 33186 110506365
Osteopenia 42.15 11.87 51 49697 22158 110517393
Plantar fasciitis 41.86 11.87 27 49721 5074 110534477
Gait spastic 41.23 11.87 18 49730 1531 110538020
Contraindicated product administered 41.02 11.87 31 49717 248236 110291315
Thrombocytopenia 40.32 11.87 59 49689 348826 110190725
Multiple sclerosis relapse 40.02 11.87 77 49671 50163 110489388
Intentional overdose 39.86 11.87 6 49742 132495 110407056
Hepatic enzyme increased 39.35 11.87 52 49696 320840 110218711
Ascites 38.36 11.87 110 49638 92698 110446853
Bronchopulmonary aspergillosis allergic 37.95 11.87 31 49717 8395 110531156
Pyrexia 37.76 11.87 243 49505 898022 109641529
Somnolence 37.73 11.87 246 49502 297203 110242348
Onychoclasis 37.68 11.87 29 49719 7208 110532343
Troponin increased 37.54 11.87 56 49692 29710 110509841
Injection site pain 37.43 11.87 169 49579 177753 110361798
Impaired healing 37.33 11.87 21 49727 196696 110342855
Product label on wrong product 37.30 11.87 8 49740 54 110539497
Neutropenia 37.12 11.87 70 49678 374550 110165001
Total lung capacity decreased 35.94 11.87 28 49720 7086 110532465
Injection site erythema 35.48 11.87 108 49640 94068 110445483
Dermatitis contact 34.93 11.87 37 49711 13916 110525635
Drug-induced liver injury 34.85 11.87 6 49742 120061 110419490
Pruritus 34.70 11.87 407 49341 581153 109958398
Cardiogenic shock 34.14 11.87 78 49670 57260 110482291
Aortic stenosis 33.35 11.87 35 49713 13024 110526527
Sensation of foreign body 33.13 11.87 28 49720 7947 110531604
Hair texture abnormal 32.62 11.87 21 49727 3933 110535618
Hypokalaemia 32.49 11.87 21 49727 182427 110357124
Intentional product misuse 32.39 11.87 132 49616 132772 110406779
Pancytopenia 32.34 11.87 28 49720 209585 110329966
Hair growth abnormal 32.22 11.87 20 49728 3517 110536034
Irritable bowel syndrome 31.93 11.87 17 49731 164198 110375353
Increased upper airway secretion 31.79 11.87 23 49725 5209 110534342
Benign prostatic hyperplasia 31.59 11.87 40 49708 18194 110521357
Burning sensation 31.53 11.87 85 49663 69127 110470424
Myelosuppression 31.51 11.87 3 49745 94337 110445214
Urinary tract infection 31.10 11.87 252 49496 326030 110213521
Renal cyst haemorrhage 31.03 11.87 12 49736 749 110538802
Bursitis 30.81 11.87 10 49738 129908 110409643
Ceruloplasmin increased 30.40 11.87 6 49742 25 110539526
Cardiac tamponade 30.12 11.87 31 49717 11276 110528275
Fibromyalgia 29.98 11.87 20 49728 170889 110368662
Spinal osteoarthritis 29.90 11.87 41 49707 20142 110519409
Ill-defined disorder 29.39 11.87 17 49731 156836 110382715
Hypertonic bladder 29.27 11.87 22 49726 5280 110534271
Interstitial lung disease 29.25 11.87 13 49735 139321 110400230
Dizziness 29.06 11.87 458 49290 697735 109841816
Product administration interrupted 28.37 11.87 30 49718 11262 110528289
Blood copper increased 28.31 11.87 6 49742 38 110539513
Septic shock 28.22 11.87 18 49730 157510 110382041
Bacteroides infection 27.85 11.87 17 49731 2902 110536649
Foreign body in throat 27.15 11.87 12 49736 1051 110538500
Feeling abnormal 27.03 11.87 156 49592 180555 110358996
Completed suicide 27.01 11.87 42 49706 242339 110297212
Bone cyst 26.96 11.87 18 49730 3585 110535966
Lip dry 26.95 11.87 6 49742 100077 110439474
Application site exfoliation 26.89 11.87 10 49738 560 110538991
Cardiac disorder 26.44 11.87 85 49663 76195 110463356
Ulcer 26.05 11.87 59 49689 43057 110496494
Depressed level of consciousness 26.00 11.87 9 49739 112269 110427282
Back pain 25.93 11.87 268 49480 370728 110168823
Osteosclerosis 25.52 11.87 19 49729 4496 110535055
Brain natriuretic peptide increased 25.05 11.87 28 49720 11181 110528370
Peripheral venous disease 24.86 11.87 4 49744 84113 110455438
Application site pruritus 24.62 11.87 18 49730 4142 110535409
Vascular anastomotic haemorrhage 24.46 11.87 8 49740 305 110539246
Intentional dose omission 24.21 11.87 37 49711 20043 110519508
Lung opacity 24.16 11.87 28 49720 11624 110527927
Coronary artery disease 24.05 11.87 79 49669 71611 110467940
Nausea 24.02 11.87 726 49022 1234964 109304587
Pollakiuria 24.00 11.87 58 49690 44137 110495414
Dysphonia 23.99 11.87 82 49666 75847 110463704
Psoriatic arthropathy 23.99 11.87 32 49716 196729 110342822
Central nervous system lesion 23.65 11.87 32 49716 15521 110524030
Delirium 23.42 11.87 16 49732 135009 110404542
White blood cell count decreased 23.40 11.87 180 49568 229210 110310341
Therapeutic response unexpected 23.38 11.87 40 49708 23803 110515748
Monoparesis 23.17 11.87 18 49730 4535 110535016
Electrocardiogram QT prolonged 23.14 11.87 10 49738 108950 110430601
Skin exfoliation 22.91 11.87 89 49659 87562 110451989
Illness 22.77 11.87 85 49663 82086 110457465
Red blood cell sedimentation rate increased 22.53 11.87 4 49744 78298 110461253
Balance disorder 22.50 11.87 108 49640 116452 110423099
Injury 22.46 11.87 28 49720 177237 110362314
Product preparation error 22.32 11.87 26 49722 10853 110528698
Joint injury 22.27 11.87 53 49695 39941 110499610
Erectile dysfunction 22.10 11.87 34 49714 18522 110521029
Diabetes mellitus 22.10 11.87 96 49652 99285 110440266
Mucosal inflammation 21.76 11.87 8 49740 96133 110443418
Epilepsy 21.59 11.87 9 49739 100200 110439351
Spinal stenosis 21.43 11.87 34 49714 19022 110520529
Blister 21.20 11.87 44 49704 227332 110312219
Suicide attempt 21.15 11.87 10 49738 103384 110436167
Inflammation 21.04 11.87 34 49714 193204 110346347
Chronic obstructive pulmonary disease 20.97 11.87 101 49647 109057 110430494
Injection site swelling 20.65 11.87 68 49680 61722 110477829
Occupational asthma 20.40 11.87 4 49744 16 110539535
Vision blurred 20.36 11.87 113 49635 128909 110410642
Prescribed overdose 20.31 11.87 7 49741 87574 110451977
Wound infection 20.25 11.87 9 49739 96456 110443095
Application site pain 20.20 11.87 18 49730 5481 110534070
Aspiration 19.82 11.87 43 49705 30490 110509061
Vena cava injury 19.68 11.87 7 49741 345 110539206
Arthropathy 19.66 11.87 65 49683 287457 110252094
Exposure during pregnancy 19.63 11.87 28 49720 167396 110372155
Hepatitis 19.54 11.87 8 49740 90046 110449505
Cytokine release syndrome 19.36 11.87 4 49744 70302 110469249
Grip strength decreased 19.31 11.87 6 49742 80168 110459383
Scrotal oedema 19.21 11.87 11 49737 1670 110537881
Full blood count abnormal 19.01 11.87 62 49686 55990 110483561
Electrocardiogram ST-T segment depression 18.92 11.87 4 49744 25 110539526
Malignant neoplasm progression 18.74 11.87 31 49717 174536 110365015
Aortic dilatation 18.71 11.87 12 49736 2234 110537317
Rhabdomyolysis 18.67 11.87 16 49732 120385 110419166
Hepatic cirrhosis 18.31 11.87 4 49744 67622 110471929
Eye irritation 18.27 11.87 44 49704 33408 110506143
Skin discolouration 18.24 11.87 56 49692 48990 110490561
Blood creatinine increased 17.81 11.87 142 49606 182747 110356804
Cardiac failure 17.75 11.87 36 49712 187590 110351961
Obesity 17.65 11.87 15 49733 113336 110426215
Abdominal wall haemorrhage 17.64 11.87 8 49740 745 110538806
Blood 25-hydroxycholecalciferol decreased 17.62 11.87 7 49741 469 110539082
Multiple sclerosis 17.61 11.87 37 49711 25661 110513890
Pre-existing condition improved 17.58 11.87 18 49730 6508 110533043
Joint swelling 17.45 11.87 122 49626 442723 110096828
Vascular compression 17.36 11.87 8 49740 773 110538778
Sleep disorder 17.09 11.87 150 49598 198494 110341057
Serotonin syndrome 17.07 11.87 3 49745 59150 110480401
Dyspnoea exertional 16.99 11.87 92 49656 103968 110435583
Eosinophilic pleural effusion 16.92 11.87 7 49741 521 110539030
Dandruff 16.86 11.87 7 49741 526 110539025
Cardiac arrest 16.76 11.87 40 49708 196713 110342838
Hyperparathyroidism secondary 16.68 11.87 13 49735 3291 110536260
Respiratory failure 16.64 11.87 46 49702 215286 110324265
Anxiety 16.51 11.87 232 49516 344846 110194705
Hot flush 16.41 11.87 66 49682 65970 110473581
Hepatic function abnormal 16.27 11.87 10 49738 89285 110450266
Product monitoring error 16.13 11.87 20 49728 8907 110530644
Treatment failure 16.12 11.87 67 49681 277167 110262384
Agranulocytosis 16.04 11.87 4 49744 61756 110477795
Injection site pruritus 15.88 11.87 55 49693 51203 110488348
Pleuritic pain 15.73 11.87 27 49721 16113 110523438
Joint range of motion decreased 15.69 11.87 19 49729 121813 110417738
Intentional product use issue 15.63 11.87 58 49690 247848 110291703
Deformity 15.60 11.87 21 49727 10139 110529412
Therapeutic product effect decreased 15.51 11.87 57 49691 244259 110295292
Hepatic cytolysis 15.44 11.87 3 49745 55050 110484501
Left ventricular hypertrophy 15.40 11.87 24 49724 13220 110526331
Carotid arteriosclerosis 15.37 11.87 12 49736 3045 110536506
Constipation 15.33 11.87 236 49512 357550 110182001
Renal artery stenosis 15.31 11.87 13 49735 3713 110535838
Pleuropericarditis 15.30 11.87 7 49741 665 110538886
Cholestasis 15.24 11.87 5 49743 64513 110475038
Cardiac hypertrophy 15.23 11.87 10 49738 1937 110537614
Upper respiratory tract infection 15.07 11.87 106 49642 131222 110408329
Rectal prolapse 14.97 11.87 11 49737 2552 110536999
Actinic keratosis 14.79 11.87 17 49731 6996 110532555
Acute respiratory distress syndrome 14.71 11.87 3 49745 53195 110486356
Skin burning sensation 14.47 11.87 31 49717 21794 110517757
Oroticaciduria 14.44 11.87 3 49745 17 110539534
Skin swelling 14.43 11.87 18 49730 8062 110531489
Dry mouth 14.22 11.87 145 49603 199803 110339748
Perineal cyst 14.20 11.87 5 49743 239 110539312
Regurgitation 13.99 11.87 12 49736 3473 110536078
Exostosis 13.97 11.87 49 49699 45907 110493644
Skin lesion 13.96 11.87 53 49695 51578 110487973
Autoimmune disorder 13.92 11.87 6 49742 65477 110474074
Drug reaction with eosinophilia and systemic symptoms 13.87 11.87 10 49738 82085 110457466
Pregnancy 13.87 11.87 3 49745 51064 110488487
Sedation 13.86 11.87 7 49741 69676 110469875
Swelling of eyelid 13.82 11.87 16 49732 6637 110532914
Limb discomfort 13.68 11.87 45 49703 40809 110498742
Intraductal papillary mucinous neoplasm 13.66 11.87 7 49741 852 110538699
Application site dryness 13.53 11.87 5 49743 275 110539276
Eye swelling 13.49 11.87 39 49709 33009 110506542
Nocturia 13.48 11.87 26 49722 16964 110522587
Drug dependence 13.46 11.87 3 49745 50017 110489534
Blepharospasm 13.40 11.87 4 49744 54847 110484704
Skin hyperpigmentation 13.39 11.87 18 49730 8678 110530873
Myocardial necrosis 13.33 11.87 6 49742 549 110539002
Respiratory symptom 13.27 11.87 24 49724 14921 110524630
Cytomegalovirus infection 13.25 11.87 4 49744 54440 110485111
Blood cholesterol abnormal 13.24 11.87 12 49736 3734 110535817
Full blood count decreased 13.21 11.87 38 49710 32061 110507490
Injection site mass 13.04 11.87 32 49716 24581 110514970
Loss of libido 13.01 11.87 11 49737 3122 110536429
Spinal operation 12.92 11.87 20 49728 10952 110528599
Electrocardiogram ST segment depression 12.82 11.87 14 49734 5447 110534104
Lower respiratory tract infection 12.77 11.87 61 49687 243045 110296506
Inappropriate schedule of product administration 12.77 11.87 144 49604 203493 110336058
Memory impairment 12.68 11.87 140 49608 196804 110342747
Haemorrhoids 12.59 11.87 40 49708 35632 110503919
Palpitations 12.56 11.87 118 49630 159094 110380457
Injection site bruising 12.55 11.87 51 49697 51212 110488339
Cardiovascular disorder 12.49 11.87 30 49718 22730 110516821
Lactic acidosis 12.46 11.87 14 49734 92797 110446754
Hypertensive emergency 12.37 11.87 11 49737 3340 110536211
Hypocalcaemia 12.36 11.87 7 49741 65359 110474192
Nasal congestion 12.27 11.87 81 49667 98201 110441350
Multiple organ dysfunction syndrome 12.25 11.87 113 49635 151597 110387954
Depressed mood 12.21 11.87 57 49691 60752 110478799
Acne 12.21 11.87 38 49710 33482 110506069
Hypertensive crisis 12.19 11.87 31 49717 24341 110515210
Skin fissures 12.12 11.87 31 49717 24427 110515124
Leukopenia 12.09 11.87 31 49717 148760 110390791
Injection site urticaria 12.05 11.87 25 49723 17190 110522361
Nasal disorder 11.99 11.87 12 49736 4222 110535329
Hypervolaemia 11.94 11.87 49 49699 49411 110490140
Delayed graft function 11.94 11.87 12 49736 4245 110535306
Vitamin D deficiency 11.89 11.87 26 49722 18526 110521025
Increased tendency to bruise 11.89 11.87 20 49728 11738 110527813
Hyperphagia 11.88 11.87 11 49737 3520 110536031

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02DC01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON
Pyrimidine derivatives
ATC D11AX01 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Other dermatologicals
FDA PE N0000175379 Arteriolar Vasodilation
FDA EPC N0000175564 Arteriolar Vasodilator
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35674 antihypertensive agent

Related Drugs by ATC class:

D11AX Other dermatologicals 20 drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Alopecia indication 56317004 DOID:987
Pericarditis contraindication 3238004 DOID:1787
Myocardial infarction contraindication 22298006 DOID:5844
Orthostatic hypotension contraindication 28651003
Cardiac tamponade contraindication 35304003 DOID:115
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Cerebrovascular disease contraindication 62914000 DOID:6713
Kidney disease contraindication 90708001 DOID:557
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Pheochromocytoma contraindication 302835009
Pericardial effusion contraindication 373945007 DOID:118
Dermatosis of scalp contraindication 402694007 DOID:3136




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.35 Basic
pKa2 2.62 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sulfonylurea receptor 2, Kir6.2 Ion channel OPENER CHEMBL SCIENTIFIC LITERATURE
ATP-sensitive inward rectifier potassium channel 1 Ion channel IC50 6.97 WOMBAT-PK

External reference:

IDSource
4018077 VUID
N0000146416 NUI
D00418 KEGG_DRUG
4018077 VANDF
C0026196 UMLSCUI
CHEBI:6942 CHEBI
MXD PDB_CHEM_ID
CHEMBL802 ChEMBL_ID
DB00350 DRUGBANK_ID
D008914 MESH_DESCRIPTOR_UI
4201 PUBCHEM_CID
4254 IUPHAR_LIGAND_ID
2987 INN_ID
5965120SH1 UNII
202706 RXNORM
1335 MMSL
2064 MMSL
5119 MMSL
7147 MMSL
d00135 MMSL
000637 NDDF
387272001 SNOMEDCT_US
49577002 SNOMEDCT_US
5965120SH1 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
good sense hair regrowth treatment HUMAN OTC DRUG LABEL 1 0113-0294 AEROSOL, FOAM 5 g TOPICAL ANDA 16 sections
Good Sense Hair Regrowth Treatment HUMAN OTC DRUG LABEL 1 0113-1032 SOLUTION 5 g TOPICAL ANDA 16 sections
Good Sense Hair Regrowth Treatment HUMAN OTC DRUG LABEL 1 0113-1129 AEROSOL, FOAM 50 mg TOPICAL ANDA 16 sections
minoxidil HUMAN OTC DRUG LABEL 1 0113-5129 AEROSOL, FOAM 50 mg TOPICAL ANDA 16 sections
GOOD SENSE HAIR REGROWTH TREATMENT HUMAN OTC DRUG LABEL 1 0113-6500 SOLUTION 2 g TOPICAL ANDA 16 sections
GOOD SENSE HAIR REGROWTH TREATMENT HUMAN OTC DRUG LABEL 1 0113-7080 AEROSOL, FOAM 5 g TOPICAL ANDA 16 sections
hair regrowth treatment HUMAN OTC DRUG LABEL 1 0363-0032 SOLUTION 5 g TOPICAL ANDA 16 sections
hair regrowth treatment HUMAN OTC DRUG LABEL 1 0363-0703 SOLUTION 2 g TOPICAL ANDA 16 sections
Solution HUMAN OTC DRUG LABEL 1 0363-2173 SOLUTION 0.02 g TOPICAL ANDA 13 sections
Solution HUMAN OTC DRUG LABEL 1 0363-2173 SOLUTION 0.02 g TOPICAL ANDA 13 sections
Minoxidil (For Men) HUMAN OTC DRUG LABEL 1 0363-9090 AEROSOL, FOAM 50 mg TOPICAL ANDA 16 sections
Minoxidil (For Women) HUMAN OTC DRUG LABEL 1 0363-9091 AEROSOL, FOAM 50 mg TOPICAL ANDA 16 sections
Minoxidil HUMAN OTC DRUG LABEL 1 0363-9970 SOLUTION 2 g TOPICAL ANDA 15 sections
Minoxidil HUMAN OTC DRUG LABEL 1 0363-9971 SOLUTION 50 mg TOPICAL ANDA 16 sections
Minoxidil HUMAN OTC DRUG LABEL 1 0363-9973 SOLUTION 50 mg TOPICAL ANDA 16 sections
Minoxidil HUMAN PRESCRIPTION DRUG LABEL 1 0591-5642 TABLET 2.50 mg ORAL ANDA 26 sections
Minoxidil HUMAN PRESCRIPTION DRUG LABEL 1 0591-5643 TABLET 10 mg ORAL ANDA 26 sections
Minoxidil (For Men) HUMAN OTC DRUG LABEL 1 11673-157 AEROSOL, FOAM 50 mg TOPICAL ANDA 16 sections
Minoxidil (For Women) HUMAN OTC DRUG LABEL 1 11673-158 AEROSOL, FOAM 50 mg TOPICAL ANDA 16 sections
up and up hair regrowth treatment for men HUMAN OTC DRUG LABEL 1 11673-317 SOLUTION 5 g TOPICAL ANDA 16 sections
up and up hair regrowth treatment for women HUMAN OTC DRUG LABEL 1 11673-919 SOLUTION 2 g TOPICAL ANDA 16 sections
Daylogic For Men HUMAN OTC DRUG LABEL 1 11822-0606 AEROSOL, FOAM 5 g TOPICAL ANDA 16 sections
minoxidil HUMAN OTC DRUG LABEL 1 11822-0702 SOLUTION 2 g TOPICAL ANDA 16 sections
hair regrowth treatment HUMAN OTC DRUG LABEL 1 11822-1260 SOLUTION 5 g TOPICAL ANDA 16 sections
hair regrowth treatment HUMAN OTC DRUG LABEL 1 11822-1260 SOLUTION 5 g TOPICAL ANDA 16 sections
hair regrowth treatment HUMAN OTC DRUG LABEL 1 11822-1323 SOLUTION 2 g TOPICAL ANDA 16 sections
hair regrowth treatment HUMAN OTC DRUG LABEL 1 21130-611 SOLUTION 5 g TOPICAL ANDA 16 sections
Loesch Hair Regrowth FormulaUnscented Topical Solution Extra-Strength for Men HUMAN OTC DRUG LABEL 1 25280-006 SOLUTION 3 g TOPICAL ANDA 10 sections
Loesch Hair Regrowth FormulaUnscented Topical Solution Regular-Strength for Men and Women HUMAN OTC DRUG LABEL 1 25280-007 SOLUTION 2 g TOPICAL ANDA 10 sections
hair regrowth treatment HUMAN OTC DRUG LABEL 1 30142-632 SOLUTION 5 g TOPICAL ANDA 16 sections